Asunto(s)
Prótesis Vascular/normas , Ensayos Clínicos como Asunto , Aprobación de Recursos , Seguridad de Equipos , Necesidades y Demandas de Servicios de Salud , Implantación de Prótesis Vascular/efectos adversos , Implantación de Prótesis Vascular/normas , Cateterismo Cardíaco/métodos , Europa (Continente) , Femenino , Humanos , Masculino , Ensayo de Materiales/normas , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/normas , Diseño de Prótesis , Administración de la SeguridadRESUMEN
The appraisal of new diagnostics or therapies performed by the Federal Joint Committee in Germany often reveals a dramatic lack of evidence of the benefit of such medical treatments. For example, the evaluation of low dose rate brachytherapy used to treat men with local prostate cancer demonstrates that controlled trials still need to be conducted to ensure evidence-based patient care. In Germany, legal incentives are missing to regularly assess the benefits of medical devices and operative techniques. For the sake of patient safety there is an urgent need for a change in law in order to initiate a systematic evaluation of these new medical technologies before their widespread use.
Asunto(s)
Braquiterapia/normas , Neoplasias de la Próstata/radioterapia , Medición de Riesgo/normas , Braquiterapia/métodos , Alemania , Humanos , Legislación Médica/normas , Masculino , Neoplasias de la Próstata/patología , Dosificación RadioterapéuticaRESUMEN
Aggrecanase activities of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) proteinases were measured with a recombinant aggrecan fragment and two monoclonal antibodies. Recombinant human aggrecan interglobular domain was first incubated in the presence of ADAMTS enzymes. The aggrecan peptide with the N-terminal sequence ARGSVIL released upon hydrolysis was then quantified in an enzyme-linked immunosorbent assay (ELISA) with an anti-neoepitope antibody specific for the N-terminal ARGSVIL sequence and a second anti-aggrecan peptide antibody. For higher sensitivity of the assay, P1-P5 residues of the aggrecanase site within the aggrecan substrate were changed by in vitro mutagenesis. Specific activities of recombinant truncated ADAMTS1 and ADAMTS4 estimated with authentic aggrecan interglobular domain amounted to 2.4 +/- 0.4 and 21.7 +/- 9.5 nmoles hydrolyzed substrate/min.mg, respectively. The values were 10.3 +/- 5.1 and 151.5 +/- 93.5 nmoles/min.mg for hydrolysis of the modified substrate. The aggrecanase activity assay can be used for (1) kinetic characterization of aggrecanase activities of human and animal ADAMTS, (2) screening of inhibitors for aggrecan hydrolyzing ADAMTS, and (3) estimation of aggrecanase activities in biological samples.
Asunto(s)
Proteínas ADAM/metabolismo , Endopeptidasas/análisis , Endopeptidasas/metabolismo , Proteínas ADAM/química , Proteínas ADAM/aislamiento & purificación , Proteína ADAMTS1 , Secuencia de Aminoácidos , Bioensayo/métodos , Western Blotting , Cromatografía en Gel , ADN Complementario/genética , Ensayo de Inmunoadsorción Enzimática , Epítopos , Humanos , Hidrólisis , Cinética , Técnicas de Amplificación de Ácido Nucleico , Reacción en Cadena de la Polimerasa , Ingeniería de Proteínas , Estructura Terciaria de Proteína , Líquido Sinovial/enzimologíaRESUMEN
Apolipophorin III (apoLp-III) is a prototype exchangeable apolipoprotein that is amenable to structure-function studies. The protein folds as a bundle of five amphipathic alpha-helices and undergoes a dramatic conformational change upon lipid binding. Recently, we have shown that a truncation mutant of Galleria mellonella apoLp-III comprising helices 1-3 is stable in solution and able to bind to lipid surfaces [Dettloff, M., Weers, P. M. M., Niere, M., Kay, C. M., Ryan, R. O., and Wiesner, A. (2001) Biochemistry 40, 3150-3157]. To investigate the role of the C-terminal helices in apoLp-III structure and function, two additional 3-helix mutants were designed: a core fragment comprising helix (H) 2-4, and a C-terminal fragment (H3-5). Each truncation mutant retained the ability to associate spontaneously with dimyristoylphosphatidylcholine (DMPC) vesicles, transforming them into discoidal complexes. The rate of apolipoprotein-dependent DMPC vesicle transformation decreased in the order H1-3 > H2-4 > H3-5. Truncation of two helices led to a significant decrease in alpha-helical content in buffer in each case, from 86% (wild-type) to 50% (H1-3), 28% (H2-4), and 24% alpha-helical content (H3-5). On the other hand, trifluoroethanol or complexation with DMPC induced the truncation mutants to adopt a high alpha-helical structure similar to that of wild-type protein (84-100% alpha-helical structure). ApoLp-III(H1-3) and apoLp-III(H2-4), but not apoLp-III(H3-5), were able to prevent phospholipase-C-induced low density lipoprotein aggregation, indicating that interaction of the C-terminal fragment with spherical lipoprotein surfaces was impaired. As lipoprotein binding is significantly affected and DMPC transformation rates are relatively slow upon removal of N-terminal helices, the data indicate that structural elements necessary for lipid interaction reside in the N-terminal part of the protein.